The trajectory of Sildenafil presents a challenging picture for those considering investment. While the initial release generated substantial returns, the expiration of its patent opened the avenue to cheaper https://bookmarksurl.com/story7303838/sildenafil-and-big-pharma-a-risky-opportunity